The Goldman Sachs Group Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

United Therapeutics (NASDAQ:UTHR) had its price target hoisted by The Goldman Sachs Group from $243.00 to $302.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a neutral rating on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the stock. Jefferies Financial Group upped their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Bank of America reduced their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. Finally, LADENBURG THALM/SH SH upped their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Trading Up 0.0 %

Shares of UTHR traded up $0.05 on Friday, reaching $374.02. The company’s stock had a trading volume of 426,943 shares, compared to its average volume of 319,868. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $377.92. The stock has a market capitalization of $16.70 billion, a PE ratio of 16.43, a PEG ratio of 1.35 and a beta of 0.56. The firm has a fifty day moving average of $355.40 and a 200-day moving average of $316.65.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the prior year, the business posted $5.38 EPS. The firm’s revenue was up 22.9% compared to the same quarter last year. As a group, equities analysts anticipate that United Therapeutics will post 24.85 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other United Therapeutics news, CFO James Edgemond sold 7,785 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at $947,597.55. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $45,293.30. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 98,412 shares of company stock worth $33,971,508. 11.90% of the stock is owned by corporate insiders.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. Wealth Enhancement Advisory Services LLC raised its position in shares of United Therapeutics by 85.4% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 2,585 shares of the biotechnology company’s stock valued at $594,000 after buying an additional 1,191 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of United Therapeutics by 0.3% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 101,042 shares of the biotechnology company’s stock valued at $23,211,000 after buying an additional 338 shares in the last quarter. State of Alaska Department of Revenue raised its position in shares of United Therapeutics by 153.5% during the 1st quarter. State of Alaska Department of Revenue now owns 16,557 shares of the biotechnology company’s stock valued at $3,802,000 after buying an additional 10,025 shares in the last quarter. First Trust Direct Indexing L.P. raised its position in shares of United Therapeutics by 38.0% during the 1st quarter. First Trust Direct Indexing L.P. now owns 2,107 shares of the biotechnology company’s stock valued at $484,000 after buying an additional 580 shares in the last quarter. Finally, Van ECK Associates Corp raised its position in shares of United Therapeutics by 4.7% during the 1st quarter. Van ECK Associates Corp now owns 10,539 shares of the biotechnology company’s stock valued at $2,421,000 after buying an additional 475 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.